retatrutide phase 2 nejm 2023 obesity trial jastreboff ๐จBreaking: Retatrutide's first 3 T2D data just dropped. โธ A1C: โ2.0% at 40 weeks โธ Weight: โ36.6 lbs (โ16.8%) at 12 mg โธ No weight loss plateau โ curve still descending retatrutide 2024 Retatrutide (not yet
Description
A moderate dosage titration method is advised to mitigate adverse effects when commencing medication (Bettge et al
GLP-1 medications are a breakthrough for weight loss and metabolic healthbut commonly cause digestive side effects that can hinder adherence
You can take injectable semaglutide at any time of the day without regard to meals
Timeline of Retatrutide Results: Week by Week The trial data shows weight loss beginning early and continuing throughout treatment
These adverse reactions are generally mild to moderate and gradually alleviated in most patients (100, 104)
